Latest Conference Articles

June 20th 2015, 8:52am

International Conference on Malignant Lymphoma

A three-drug combination comprising the novel Bcl-2 inhibitor venetoclax, bortezomib, and dexamethasone demonstrated a clinical benefit in heavily pretreated patients with relapsed/refractory multiple myeloma.

June 20th 2015, 8:08am

International Conference on Malignant Lymphoma

Lenalidomide in combination with rituximab and as maintenance monotherapy is highly active in patients with relapsed/refractory central nervous system non-Hodgkin lymphoma.

June 20th 2015, 6:00am

International Conference on Malignant Lymphoma

Carolina Moreno Atanasio, MD, University of Barcelona, discusses an ongoing phase III study comparing ibrutinib and obinutuzumab with chlorambucil and obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

June 19th 2015, 3:32pm

International Conference on Malignant Lymphoma

Adrian Wiestner, MD, PhD, National Institutes of Health, National Heart, Lung, and Blood Services, discusses findings from the phase III HELIOS trial, which explored the addition of ibrutinib to bendamustine and rituximab for patients with relapsed/refractory chronic lymphocytic leukemia.

June 19th 2015, 2:14pm

International Conference on Malignant Lymphoma

A chemotherapy-free combination of the anti-CD20 antibody ublituximab, ibrutinib, and the PI3K delta inhibitor TGR-1202 demonstrated robust clinical activity in patients with relapsed/refractory chronic lymphocytic leukemia or B-cell non-Hodgkin lymphoma.

June 19th 2015, 1:12pm

International Conference on Malignant Lymphoma

The PI3Kδ inhibitor INCB040093 alone or in combination with the JAK1 inhibitor INCB039110 showed early promise in relapsed/refractory classical Hodgkin lymphoma.

June 19th 2015, 11:01am

International Conference on Malignant Lymphoma

Susan M. O'Brien, MD, associate director, Clinical Science Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, Chao Family Comprehensive Cancer Center, University of California at Irvine, discusses the use of ibrutinib and idealisib in chronic lymphocytic leukemia (CLL).

June 19th 2015, 8:04am

International Conference on Malignant Lymphoma

Nivolumab continued to show high activity and a good safety profile after more than a year of follow-up in heavily pretreated patients with relapsed or refractory lymphoid malignancies or those with classical Hodgkin lymphoma.

June 18th 2015, 12:35pm

International Conference on Malignant Lymphoma

The MATRIX regimen, comprised of a methotrexate/cytarabine backbone plus thiotepa and rituximab, improved outcomes in patients with primary CNS lymphoma.

June 18th 2015, 12:05pm

International Conference on Malignant Lymphoma

TAK-659, an inhibitor of spleen tyrosine kinase, showed early signs of antitumor activity in patients with lymphoma, with two expansion arms planned for patients with diffuse large B-cell lymphoma and chronic lymphocytic leukemia.

June 18th 2015, 11:26am

International Conference on Malignant Lymphoma

Thomas S. Uldrick, MD, staff clinician, HIV and AIDS Malignancy Branch, Center for Cancer Research at the National Institutes of Health, discusses long-term data from a study examining rituximab plus liposomal doxorubicin in HIV-infected patients with Kaposi sarcoma (KS) herpes virus-associated multicentric Castleman disease.

June 18th 2015, 6:37am

International Conference on Malignant Lymphoma

Interim PET-CT scanning was successfully used to adapt treatment regimens in patients with advanced classical Hodgkin lymphoma.

June 17th 2015, 3:07pm

International Conference on Malignant Lymphoma

Adrian Wiestner, MD, PhD, Senior Investigator, Laboratory of Lymphoid Malignancies, National Institutes of Health, National Heart, Lung, and Blood Services discusses the findings of the RESONATE II trial, which looked at chlorambucil versus ibrutinib as first-line therapy in patients older than 65 with chronic lymphocytic leukemia (CLL).

June 5th 2015, 1:23pm

ASCO Annual Meeting

The combination of lenvatinib and everolimus more than doubled progression-free survival and extended overall survival by 10.1 months compared with everolimus alone as a second-line treatment for patients with metastatic renal cell carcinoma.

June 3rd 2015, 2:35pm

ASCO Annual Meeting

Brian A. Van Tine, MD, PhD, Assistant Professor Department of Medicine Siteman Cancer Center, Washington University School of Medicine, discusses trabectedin (Yondelis) for the treatment of soft tissue sarcomas.

June 3rd 2015, 1:29pm

ASCO Annual Meeting

Progression-free survival in relapsed myeloma doubled among patients treated with carfilzomib, rather than bortezomib, in combination with dexamethasone, a randomized trial showed.

June 3rd 2015, 12:01pm

ASCO Annual Meeting

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, compares the use of anastrozole to tamoxifen in patients with ductal carcinoma in situ (DCIS).

June 3rd 2015, 11:04am

ASCO Annual Meeting

Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, discusses the PALOMA3 trial.

June 3rd 2015, 9:44am

ASCO Annual Meeting

Monoclonal antibodies against PD-1 and PD-L1 have demonstrated encouraging signs of antitumor activity for patients with pretreated advanced ovarian cancer.

June 3rd 2015, 9:04am

ASCO Annual Meeting

Trabectedin reduced the risk of disease progression by 45% versus dacarbazine in patients with advanced soft tissue sarcoma.